Innodem Neurosciences Receives 6 Million US Dollars of Financing From Morningside Group
MONTREAL, Jan. 19, 2021 /PRNewswire/ -- Innodem Neurosciences, a Montreal-based company, has closed a Series A financing round led by Morningside Ventures to support the development and commercialization of its proprietary, patented, digital biomarking technology of neurodegenerative diseases such as Multiple Sclerosis (MS), Alzheimer's disease, Parkinson's disease and related disorders, Frontotemporal Dementia and related disorders and Cancer-Related Cognitive Impairment ("chemo brain").